

Lumito receives patent approval in India

Lumito AB (publ) ("Lumito" or the "Company") today announces that the Company has been granted a patent in India relating to its technology for tissue analysis using upconverting nanoparticles. The patent has previously been granted in Europe and the United States and further strengthens Lumito's international intellectual property protection.

The granted patent protects the technology that enables imaging of samples with very high sensitivity and precision using upconverting nanoparticles. The technology is used to visualise markers in tissue samples and bodily fluids and constitutes the core of Lumito's product SCIZYS.

The patent approval in India strengthens Lumito's position in a market characterised by a rapidly growing healthcare sector, alongside strong development within research and medical technology. Patent protection in India is considered strategically important, both from a long-term commercial perspective and for future partnerships and collaborations.

"The approval of our product patent in India represents an important step in building a strong and global patent portfolio around our technology. Together with previous approvals in Europe and the United States, this provides broader commercial protection and strengthens our position ahead of future collaborations and market expansion," says Sanna Wallenborg, CEO of Lumito.

For further information, please contact:

Sanna Wallenborg, CEO Lumito

E-mail: sw@lumito.se

Ph: +4670-870 01 68

About Lumito

Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments

[Lumito receives patent approval in India](#)